Program
GW906
A development code. Also written as “GW906 injection”.
Its studies are mostly in Hypertension, led by Shenzhen Salubris Pharmaceuticals.
Furthest: phase 2, since Sep 17, 20264 company-led studies, 3 open or runningNext primary completion: Oct 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals | 43 open or running | phase 2since Sep 17, 2026 | Sep 17, 2026 | Oct 2027phase 2 · NCT07835984 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 17, 2026First study: phase 1 study in HypertensionFirst studyNCT07884461 · 40 enrolled · China
- Sep 17, 20262 phase 2 studies in HypertensionNCT07835984, NCT07835971
- Sep 18, 2026No phase study in HypertensionNCT07879755 · 1,500 planned · China
Ahead
- Oct 2027Primary completion: phase 2 study in HypertensionNCT07835984
- Jan 30, 2029Primary completion: no phase study in HypertensionNCT07879755
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07879755Hypertension · China | – | Recruiting | Jan 30, 2029 | 1,500 |
| NCT07884461Hypertension · China | 1 | Completed | Aug 24, 2026 | 40 |
| NCT07835984Hypertension · China | 2 | Not yet recruiting | Oct 2027 | 560 |
| NCT07835971Hypertension · China | 2 | Active, not recruiting | Sep 15, 2026 | 319 |
How it is read
Names in the registry
- “GW906”, 3 entries
- “GW906 injection”, 1 entry
Codes read as this program: GW906.
Conditions, from the studies’ own filings
- Hypertension, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.